Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Lessons From Lockdown: HCC and Liver Transplant Care in the COVID-19 Era—Audio Recap

In this engaging dialogue, 2 expert hepatologists discuss strategies for maintaining and even improving care of patients with HCC or liver transplantation despite the challenges posed by the COVID-19 pandemic.
Graham R. Foster, FRCP, PhD
Paul Y. Kwo, MD
Released: March 23, 2022

In this episode, Graham R. Foster, FRCP, PhD, and Paul Y. Kwo, MD, share lessons learned in the management of HCC and liver transplantation the COVID-19 era, including:

  • Global impact of HCC and strategies for maintaining HCC care in the COVID-19 era
  • Characteristics of liver transplant recipients in the COVID-19 era
  • Impact of COVID-19 pandemic period on liver transplant outcomes
  • Impact of liver transplant status on COVID-19 outcomes

Information on this Educational Activity

Faculty

Graham R. Foster, FRCP, PhD

Professor of Hepatology
The Liver Unit
Consultant Hepatologist
Queen Mary University of London
London, United Kingdom

Graham R. Foster, FRCP, PhD, has disclosed that he has received consulting fees from Biogen, GlaxoSmithKline, and UniQure and fees for non-CME/CE services from AbbVie, Gilead Sciences, and MSD.
Paul Y. Kwo, MD

Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California

Paul Y. Kwo, MD, has disclosed that he has received consulting fees from AbbVie, Aligos, Antios, Drug Farm, Enanta, Gilead Sciences, and Janssen and funds for research support from Assembly, Bristol-Myers Squibb, Eiger, Gilead Sciences, and Janssen.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grants provided by:
AbbVie
Gilead Sciences, Inc.

Related Content

Clinical Care Options (CCO) expert audio: Dr Carla Coffin discusses investigational HBV cure strategies

person default Carla Coffin, MD Released: June 30, 2022

Clinical Care Options (CCO) commentary from a patient who shares their experience of severe liver disease from HBV/HDV coinfection

person default Joaquín (Patient) Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: June 29, 2022 Expired: June 28, 2023

Patient perspectives and key action items to address in clinical settings to reduce HBV care barriers in the United States, from Clinical Care Options (CCO)

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD Jennifer Wild, MS, BSN, RN, OCN Released: June 22, 2022

Clinical Care Options (CCO) commentary from Dr Carla Coffin on risks vs benefits of treating patients in the indeterminate category for HBV treatment

person default Carla Coffin, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: June 21, 2022 Expired: June 20, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings